Madrigal Pharmaceuticals (MDGL) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Madrigal Pharmaceuticals (MDGL) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 10.1% versus a loss of 2.0%. Over five years, MDGL leads with a +447.5% price change compared with +69.9% for PTCT. Madrigal Pharmaceuticals is the larger company by market cap ($10.90 billion vs $5.40 billion), about 2.0 times the size.
On valuation, PTC Therapeutics trades at a lower forward P/E (27.3x vs 49.0x for Madrigal Pharmaceuticals). PTC Therapeutics converts more of its revenue into profit, with a net margin of 39.4% versus -30.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDGL | PTCT |
|---|---|---|
| Share price | $471.75 | $64.70 |
| Market cap | $10.90B | $5.40B |
| 1-day change | -1.08% | +3.42% |
| YTD return | -18.99% | -14.82% |
| 1-year return | +10.14% | -1.98% |
| 5-year return | +447.46% | +69.86% |
| Forward P/E | 49.01 | 27.30 |
| EPS (TTM) | $-12.85 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $958.40M | $1.73B |
| Revenue growth (YoY) | +432.05% | +114.51% |
| Net income (latest FY) | $-288.28M | $682.64M |
| Operating margin | -31.31% | 50.09% |
| Net margin | -30.08% | 39.44% |
| 52-week high | $615.00 | $90.87 |
| 52-week low | $393.61 | $61.23 |
| Distance from 52-week high | -23.29% | -28.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +44.59% | +56.21% |
| Average volume | 289.24K | 1.14M |
| Shares outstanding | 23.10M | 83.46M |
| Employees | 915 | 991 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Madrigal Pharmaceuticals is about 2.0 times larger than PTC Therapeutics by market value ($10.90B vs $5.40B).
- MDGL has outperformed PTCT by 12.1 percentage points over the past year.
- PTC Therapeutics is more profitable, keeping 39.4 cents of every revenue dollar as net income versus -30.1 cents for Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +114.51%).
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Healthcare · Biotechnology · 915 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Healthcare · Biotechnology · 991 employees
MDGL vs PTCT FAQ
Which is bigger, Madrigal Pharmaceuticals or PTC Therapeutics?
Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $10.90B compared with $5.40B for PTC Therapeutics (PTCT).
Which stock has performed better over the past year, MDGL or PTCT?
MDGL returned +10.14% over the past 12 months, compared with -1.98% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are Madrigal Pharmaceuticals and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.